Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in Chicago, USA, on 14–16 November 2026, hosted by the American Heart Association.

Bringing together global leaders in cardiovascular science, this premier event showcases groundbreaking research, clinical innovations, and collaborative strategies to advance heart health worldwide.

Representing Richmond Pharmacology

  • Dr Jörg Taubel, Chief Executive Officer

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Novel therapies and clinical trial strategies for cardiovascular disease
  • Biomarker-driven approaches to improve trial efficiency
  • Regulatory pathways for emerging treatments
  • Patient-centric recruitment and engagement strategies
  • Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AHA Scientific Sessions 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

Latest news

Richmond Pharmacology Appoints Adam Hurd as Operations Director

August 17, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Adam Hurd as Operations Director
Read more

Upcoming Event

Women's Health Horizons 2026

22 September 2026
Richmond Pharmacology is pleased to join the Women’s Health Horizons London Summit hosted by the Royal College of Obstetricians and Gynaecologists in London, 22 September 2026
View event